Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study reveals how psoriasis drug enters breast milk

NCT ID NCT06476834

First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 23 times

Summary

This completed Phase 4 study looked at how much deucravacitinib (SOTYKTU®), a drug for plaque psoriasis, passes into breast milk. Eight healthy lactating women took a single dose, and researchers measured drug levels in their milk and blood. The goal was to estimate how much of the drug a nursing infant might consume, helping guide future recommendations for breastfeeding mothers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Local Institution - 0001

    Las Vegas, Nevada, 89113-2246, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Deucravacitinib (SOTYKTU®)

What this could lead to

If successful, this study could help doctors understand how much deucravacitinib passes into breast milk, guiding safer use during breastfeeding.

What could go wrong

This is a very small study (8 participants) in healthy volunteers, not patients. Results may not apply to all women or those with medical conditions.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.